News Sentiment

RDY sentiment intelligence

Dr. Reddy’s Laboratories Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 41 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 13.29 Week of 19 Jun 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

90/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 10

high-authority source matches

Trend context Trend inactive

-0.1% over one week, -2.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Dr. Reddy’s (NYSE: RDY) schedules July 22 board meeting, shuts trading window

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 90/100 classification
One-week reaction -0.1% Price digesting
Trend fit Trend inactive -2.3% over four weeks
Fair value -6.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 18
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
MarketWatch 9
scanx.trade 4
ChartMill 3
GuruFocus 2
AD HOC NEWS 2
Simply Wall Street 1
MarketBeat 1

Event Lens

What the news is about

Classified themes
Market update 34
Capital return 2
Deals and strategy 2
Regulatory and legal 2
Earnings 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 41
scanx.trade Direct company coverage

Dr Reddy's fixes July 23 for AGM, recommends Rs.8 dividend

Dr Reddy's Laboratories has scheduled its 42nd Annual General Meeting for July 23, 2026, to be held virtually, and has recommended a final dividend of Rs.8 per equity share for the financial year ended March 31, 2026. The record date for dividend entitlement is July 10, 2026, wit

Tone
Positive 67/100
Event
Capital return
Published
20 Jun 2026 08:10
Source
scanx.trade
Simply Wall Street Direct company coverage

Will XACDURO Licensing Deal With Dr. Reddy’s Reshape Innoviva’s (INVA) Infectious Disease Strategy?

Innoviva, Inc., through its subsidiary Innoviva Specialty Therapeutics, has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories for XACDURO® in South and Central America, the Caribbean, Russia, and CIS countries. This deal expands XACDURO®

Tone
Positive 63/100
Event
Deals and strategy
Published
19 Jun 2026 07:40
Source
Simply Wall Street
MarketWatch Direct company coverage

Dr. Reddy's Laboratories rises Friday, outperforms market

Dr. Reddy's Laboratories (500124) shares increased by 0.30% on Friday, reaching 1,271.55 Indian rupees, thereby outperforming the broader market as the BSE SENSEX Index fell by 0.78%. Despite the rise, the company's stock closed 7.59% below its 52-week high.

Tone
Positive 64/100
Event
Market update
Published
19 Jun 2026 06:30
Source
MarketWatch
MarketWatch Direct company coverage

Dr. Reddy's Laboratories slips Thursday, underperforms competitors

Dr. Reddy's Laboratories Ltd. shares fell by 0.09% to 1,267.80 Indian rupees on Thursday, underperforming the broader market which saw the BSE SENSEX Index rise by 0.33%. The company's stock closed 7.86% below its 52-week high reached on April 29th.

Tone
Negative 20/100
Event
Market update
Published
18 Jun 2026 06:30
Source
MarketWatch
Chain Drug Review Direct company coverage

Dr. Reddy's launches bosutinib, generic of Bosulif

Dr. Reddy's Laboratories has launched bosutinib tablets 400mg, a generic equivalent of Wyeth's Bosulif, in collaboration with MSN Laboratories Private Ltd. This first-to-file product is eligible for 180 days of generic drug exclusivity in the U.S. and strengthens Dr. Reddy's onco

Tone
Positive 72/100
Event
Market update
Published
17 Jun 2026 15:10
Source
Chain Drug Review
MarketWatch Direct company coverage

Dr. Reddy's Laboratories slips Wednesday, underperforms market

Dr. Reddy's Laboratories Ltd. shares fell 0.63% to 1,269.00 Indian rupees on Wednesday, despite a favorable trading session for the overall market where the BSE SENSEX Index rose 0.45%. The company's stock closed 7.78% below its 52-week high of 1,376.00 rupees, which was reached

Tone
Negative 39/100
Event
Market update
Published
17 Jun 2026 06:30
Source
MarketWatch
Investing.com Canada Direct company coverage

Innoviva unit signs distribution deal with Dr. Reddy’s By Investing.com

Innoviva Specialty Therapeutics has partnered with Dr. Reddy’s Laboratories for the distribution and licensing of its antibiotic, XACDURO, across South and Central America, the Caribbean, Russia, and CIS countries. XACDURO is an antibiotic approved for hospital-acquired bacterial

Tone
Positive 64/100
Event
Deals and strategy
Published
16 Jun 2026 12:40
Source
Investing.com Canada
MarketWatch Direct company coverage

Dr. Reddy's Laboratories falls Tuesday, underperforms market

Dr. Reddy's Laboratories Ltd. saw its shares fall by 0.17% on Tuesday, closing at 1,277.05 Indian rupees, despite a generally favorable trading session where the BSE SENSEX Index rose by 0.71%. The company's stock is now 7.19% below its 52-week high of 1,376.00 rupees, which was

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 06:30
Source
MarketWatch
Stock Titan Direct company coverage

Dr. Reddy’s (NYSE: RDY) debuts first-to-market generic Bosulif 400mg in U.S.

Dr. Reddy’s Laboratories has launched Bosutinib Tablets 400mg, a first-to-market generic equivalent of Bosulif, in the U.S. This oncology therapy is eligible for 180 days of generic drug exclusivity for the 400mg strength, with Dr. Reddy's holding exclusive marketing rights while

Tone
Positive 71/100
Event
Market update
Published
15 Jun 2026 10:10
Source
Stock Titan
MarketWatch Direct company coverage

Dr. Reddy's Laboratories rises Monday, outperforms competitors

Dr. Reddy's Laboratories Ltd. shares rose 0.42% to 1,279.25 Indian rupees on Monday, outperforming its competitors and the BSE SENSEX Index, which climbed 0.97%. The company's stock closed 7.03% below its 52-week high achieved on April 29th.

Tone
Positive 70/100
Event
Market update
Published
15 Jun 2026 06:30
Source
MarketWatch
GuruFocus Direct company coverage

Dr. Reddy's (RDY) Launches Generic Bosutinib Tablets in the U.S.

Dr. Reddy's Laboratories has launched generic Bosutinib Tablets (400mg) in the U.S., making it the first to offer this generic version of Bosulif. This move expands the company's oncology lineup, providing a cost-effective alternative for chronic myeloid leukemia patients and sol

Tone
Positive 75/100
Event
Market update
Published
14 Jun 2026 21:36
Source
GuruFocus
lincolnjournal.com Direct company coverage

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Dr. Reddy's Laboratories has launched Bosutinib Tablets 400mg in the United States, a generic version of Bosulif®, marking a significant expansion of its oncology portfolio. This first-to-market launch was achieved in collaboration with MSN Laboratories, with Dr. Reddy's holding

Tone
Positive 71/100
Event
Market update
Published
13 Jun 2026 22:10
Source
lincolnjournal.com
Fortune India Direct company coverage

Dr Reddy’s launches generic Bosulif in US, secures 180-day exclusivity

Dr. Reddy's Laboratories has launched Bosutinib Tablets 400 mg in the US, becoming the first generic competitor to Pfizer's Bosulif, a treatment for chronic myeloid leukaemia. This launch provides the company with 180 days of market exclusivity and strengthens its oncology portfo

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 12:39
Source
Fortune India
Business Standard Direct company coverage

Dr. Reddy's Labs oncology drug Bosutinib Tablets in United States

Dr. Reddy's Laboratories has launched Bosutinib Tablets 400 mg, a generic equivalent of Bosulif, in the United States, in collaboration with MSN Laboratories. This first-to-market launch expands Dr. Reddy's oncology portfolio and is eligible for 180-days of generic drug exclusivi

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 11:39
Source
Business Standard
Business Wire Direct company coverage

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif

Dr. Reddy's Laboratories has launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States. This first-to-market launch was developed in collaboration with MSN Laboratories and expands Dr. Reddy's oncology portfolio, aiming to increase patient access to

Tone
Positive 72/100
Event
Market update
Published
13 Jun 2026 10:39
Source
Business Wire
scanx.trade Direct company coverage

Dr Reddy's launches first-to-market Bosutinib in US

Dr Reddy's Laboratories has launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, securing 180 days of market exclusivity. This strategic launch, developed in collaboration with MSN Laboratories, expands Dr Reddy's oncology portfolio and aims to

Tone
Positive 74/100
Event
Market update
Published
13 Jun 2026 08:10
Source
scanx.trade
scanx.trade Direct company coverage

Dr Reddys promoters report no share encumbrance in FY26

Dr Reddys Laboratories has announced that its promoters and persons acting in concert did not encumber any company shares during the financial year FY26. This disclosure was made to the stock exchanges in compliance with SEBI regulations, ensuring regulatory transparency. The fil

Tone
Positive 66/100
Event
Regulatory and legal
Published
13 Jun 2026 01:10
Source
scanx.trade
MarketWatch Direct company coverage

Dr. Reddy's Laboratories slides Friday, underperforms market

Dr. Reddy's Laboratories Ltd. (500124) shares declined by 0.09% on Friday, closing at 1,273.90 Indian rupees, even as the overall market BSE SENSEX Index rose by 2.30%. The company's stock is currently trading 7.42% below its 52-week high of 1,376.00 rupees, achieved on April 29t

Tone
Negative 36/100
Event
Market update
Published
12 Jun 2026 06:30
Source
MarketWatch
MarketWatch Direct company coverage

Dr. Reddy's Laboratories rallies Thursday, underperforms competitors

Dr. Reddy's Laboratories Ltd. shares increased by 0.26% on Thursday, ending the trading session at 1,275.05 Indian rupees, despite a broader market decline. The company's stock underperformed the BSE SENSEX Index, which fell by 0.20%. Dr. Reddy's Laboratories closed 7.47% below i

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 06:30
Source
MarketWatch
Telugu Times Direct company coverage

Dr Reddys CFO MV Narasimham Wins Top Pharma Award

Dr. Reddy's Laboratories Ltd. CFO, M. V. Narasimham, has been awarded 'Best CFO in Pharmaceuticals' for 2026 at the 9th BW CFO World's Best CFO & Finance Strategy Excellence Awards. This accolade recognizes his significant contributions to building a robust global finance functio

Tone
Positive 75/100
Event
Market update
Published
11 Jun 2026 00:40
Source
Telugu Times
Deccan Chronicle Direct company coverage

Dr. Reddy’s CFO M.V. Narasimham recognized as Best CFO in Pharmaceuticals for 2026

Dr. Reddy's Laboratories Ltd. announced that its CFO, M.V. Narasimham, has been awarded 'Best CFO in Pharmaceuticals' at the 9th BW CFO World's Best CFO & Finance Strategy Excellence Awards 2026. This recognition highlights his contribution to building a robust finance function a

Tone
Positive 86/100
Event
Market update
Published
10 Jun 2026 20:00
Source
Deccan Chronicle
The Times of India Direct company coverage

HC dismisses Dr Reddy’s plea against CCI

The Telangana High Court has dismissed a writ petition filed by Dr Reddy's Laboratories against the Competition Commission of India (CCI). The pharma giant challenged ongoing proceedings alleging anti-competitive practices, but the court ruled against interference in a statutory

Tone
Negative 39/100
Event
Market update
Published
10 Jun 2026 18:10
Source
The Times of India
Stock Titan Direct company coverage

[6-K] DR REDDYS LABORATORIES LTD Current Report (Foreign Issuer) | RDY SEC Filing - Form 6-K

Dr. Reddy's Laboratories Limited filed a Form 6-K announcing its participation in an Investec investor conference in London from June 16-17, 2026. The company's management will hold in-person group meetings between 09:00 and 17:00 BST. This schedule is subject to change based on

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 15:39
Source
Stock Titan